Integrated DNA Technologies has launched two next-gen sequencing-based disease panels.
The xGen Inherited Disease Panel was designed in collaboration with Emory Genetics Laboratory and targets all the exons of genes in the Human Gene Mutation Database. The xGen Pan-Cancer Panel is based on the findings of the Cancer Genome Atlas and targets coding regions in 127 genes implicated in 12 tumor types.
Both panels feature xGen Lockdown Probes, which are 120-mer oligonucleotides with a 5' biotin modification.
The Center for Genomics and Transcriptomics has launched 11 next-gen sequencing panels for the diagnosis of hereditary skin diseases. Sequencing is performed on Illumina's HiSeq 2500 and potentially pathogenic variants are validated with capillary sequencing. The panels range in size from 7 genes to 55 genes and can be ordered individually or in combination.
Syapse plans to make third-party commercial omics interpretation providers' content available to hospitals and laboratories through the Syapse platform to enable clinical interpretation, reporting, and decision support. It will also make public and open databases like ClinVar, COSMIC, PhenoDB, and OMIM accessible through its platform.